North America antiviral drugs market is expected to reach USD 63,215.26 million by 2030 from USD 41,359.32 million in 2022, growing with a CAGR of 5.5% during the forecast period from 2023 to 2030. Market Segmentation: North America Antiviral Drugs Market, By Indication (Influenza, Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Respiratory Syncytial Virus (RSV), Herpes Simplex Virus, Human Cytomegalovirus (HCMV), Varicella-Zoster Virus (VZV), Hepatitis B Virus (HBV), Coronavirus Infection, and Others), Patient Type (Child, Adult, and Geriatric), Products (Oral, Topical, and Parenteral), Drug Type (Generic and Branded), End User (Hospitals, Clinics, Home Healthcare, Specialty Centers, Ambulatory Centers, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2030. Overview of North America Antiviral Drugs Market Dynamics : Driver • Rising prevalence of viral infections Restrain • High cost of antiviral drugs Opportunity • Increasing collaboration and partnership among key players Market Players: Some of the key market players operating in the North America antiviral drugs market are listed below: • Gilead Sciences, Inc. • F. Hoffmann-La Roche Ltd • GLAXOSMITHKLINE PLC • Abbvie • Merck & Co., Inc. • Johnson & Johnson Services, Inc. • Bristol-Myers Squibb Company • Cipla Inc. • Aurobindo Pharma • Dr. Reddy’s Laboratories Ltd. • Zydus Pharmaceuticals, Inc. • Mylan Pharmaceuticals ULC • Teva Pharmaceuticals USA, Inc. • EMERGENT • Sun Pharmaceutical Industries Ltd. • Avet Pharmaceuticals Inc. • Pfizer Inc. • SIGA Technologies • NAVINTA LLC. • Macleods Pharmaceuticals Ltd. • BioCryst Pharmaceuticals, Inc • Hetero

1 INTRODUCTION 119 1.1 OBJECTIVES OF THE STUDY 119 1.2 MARKET DEFINITION 119 1.3 OVERVIEW OF THE NORTH AMERICA ANTIVIRAL DRUGS MARKET 119 1.4 LIMITATIONS 121 1.5 MARKETS COVERED 121 2 MARKET SEGMENTATION 127 2.1 MARKETS COVERED 127 2.2 GEOGRAPHICAL SCOPE 128 2.3 YEARS CONSIDERED FOR THE STUDY 129 2.4 CURRENCY AND PRICING 129 2.5 DBMR TRIPOD DATA VALIDATION MODEL 130 2.6 MULTIVARIATE MODELLING 133 2.7 PRODUCT TYPE LIFELINE CURVE 133 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 134 2.9 DBMR MARKET POSITION GRID 135 2.10 MARKET TESTING TYPE COVERAGE GRID 136 2.11 VENDOR SHARE ANALYSIS 137 2.12 SECONDARY SOURCES 138 2.13 ASSUMPTIONS 138 3 EXECUTIVE SUMMARY 139 4 PREMIUM INSIGHTS 142 4.1 PORTER’S FIVE FORCES 143 4.2 PESTEL ANALYSIS 144 5 EPIDEMIOLOGY 145 6 PIPELINE ANALYSIS FOR NORTH AMERICA ANTIVIRAL DRUGS MARKET 146 7 REGULATORY FRAMEWORK 147 8 MARKET OVERVIEW 149 8.1 DRIVERS 151 8.1.1 RISING PREVALENCE OF VIRAL INFECTIONS 151 8.1.2 ADVANCEMENTS IN NEW ANTIVIRAL DRUG DEVELOPMENT 151 8.1.3 GROWING DEMAND FOR COMBINATION THERAPIES 153 8.1.4 INCREASING GOVERNMENT FUNDING AND R&D ACTIVITIES 153 8.2 RESTRAINS 154 8.2.1 HIGH COST OF ANTIVIRAL DRUGS 154 8.2.2 EMERGENCE OF DRUG-RESISTANT STRAINS OF VIRUSES 154 8.3 OPPORTUNITIES 155 8.3.1 INCREASING COLLABORATION AND PARTNERSHIP AMONG KEY PLAYERS 155 8.3.2 RISING NOVEL DRUG DELIVERY SYSTEMS 155 8.3.3 DEVELOPMENT OF PERSONALIZED MEDICINES 156 8.4 CHALLENGES 157 8.4.1 PATENT EXPIRATION OF ANTIVIRAL DRUGS 157 8.4.2 DEMAND FOR ALTERNATIVE MEDICINES 158 9 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY INDICATION 159 9.1 OVERVIEW 160 9.2 INFLUENZA 163 9.2.1 NEURAMINIDASE INHIBITORS 164 9.2.1.1 OSELTAMIVIR 164 9.2.1.2 ZANAMIVIR 164 9.2.1.3 PERAMIVIR 164 9.2.1.4 LANINAMIVIR 164 9.2.2 M2 INHIBITORS 165 9.2.2.1 RIMANTADINE 165 9.2.2.2 OTHERS 165 9.2.3 RNA POLYMERASE INHIBITORS 165 9.2.3.1 FAVIPIRAVIR 165 9.2.3.2 BALOXAVIR MARBOXIL 165 9.3 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 166 9.3.1 REVERSE TRANSCRIPTASE INHIBITORS 167 9.3.1.1 NUCLEOSIDE (NRTIS) 167 9.3.1.1.1 LAMIVUDINE 168 9.3.1.1.2 ABACAVIR 168 9.3.1.1.3 DIDANOSINE 168 9.3.1.1.4 OTHERS 168 9.3.1.2 NONNUCLEOSIDE (NNRTIS) 168 9.3.1.2.1 EFAVIRENZ 168 9.3.1.2.2 NEVIRAPINE 168 9.3.1.2.3 DELAVIRDINE 168 9.3.1.2.4 OTHERS 169 9.3.1.3 INTEGRASE 169 9.3.1.3.1 DOLUTEGRAVIR 169 9.3.1.3.2 ELVITEGRAVIR 169 9.3.1.3.3 RALTEGRAVIR 169 9.3.1.3.4 BICTEGRAVIR 169 9.3.1.4 NUCLEOTIDE 169 9.3.1.4.1 TENOFOVIR 170 9.3.1.4.2 OTHERS 170 9.3.1.5 INTERFERONS 170 9.3.1.5.1 ALPHA 170 9.3.1.5.2 BETA 170 9.3.1.5.3 GAMMA 171 9.3.1.6 GP41 171 9.3.1.6.1 ENFUVIRTIDE 171 9.3.1.6.2 OTHERS 171 9.3.2 PROTEASE 172 9.3.2.1 ATAZANAVIR 172 9.3.2.2 DARUNAVIR 172 9.3.2.3 LOPINAVIR 172 9.3.2.4 RITONAVIR 172 9.3.2.5 SAQUINAVIR 172 9.3.2.6 INDINAVIR 172 9.3.2.7 NELFINAVIR 173 9.3.2.8 TIPRANAVIR 173 9.3.2.9 AMPRENAVIR 173 9.4 HEPATITIS C VIRUS 173 9.4.1 NS5B POLYMERASE 174 9.4.1.1 SOFOSBUVIR 174 9.4.1.2 DASABUVIR 174 9.4.2 NS3/4A PROTEASE 175 9.4.2.1 DANOPREVIR 175 9.4.2.2 GLECAPREVIR 175 9.4.2.3 GRAZOPREVIR 175 9.4.2.4 PARITAPREVIR 175 9.4.2.5 SIMEPREVIR 175 9.4.3 NS5A PHOSPHOPROTEIN 176 9.4.3.1 LEDIPASVIR 176 9.4.3.2 VELPATASVIR 176 9.4.3.3 OMBITASVIR 176 9.4.3.4 ELBASVIR 176 9.4.3.5 DACLATASVIR 176 9.4.3.6 PIBRENTASVIR 176 9.4.4 NEURAMINIDASE 177 9.4.4.1 OSELTAMIVIR 177 9.4.4.2 ZANAMIVIR 177 9.4.4.3 PERAMIVIR 177 9.4.4.4 LANINAMIVIR 177 9.4.5 RNA POLYMERASE 177 9.4.5.1 BALOXAVIR MARBOXIL 178 9.4.5.2 FAVIPIRAVIR 178 9.4.6 MATRIX PROTEIN 2 178 9.4.6.1 RIMATIDINE 178 9.4.6.2 FAVIPIRAVIR 178 9.5 HERPES SIMPLEX VIRUS 179 9.5.1 DNA POLYMERASE UL30 180 9.5.1.1 ACICLOVIR 180 9.5.1.2 FAMCICLOVIR 180 9.5.1.3 VALACICLOVIR 180 9.5.1.4 PENCICLOVIR TRIFLURIDINE 180 9.5.1.5 BRIVUDINE 180 9.5.1.6 FOSCARNET 180 9.5.1.7 IDOXURIDINE 181 9.5.2 ENVELOPE PROTEINS 181 9.5.2.1 DOCOSANOL 181 9.5.2.2 OTHERS 181 9.6 HUMAN CYTOMEGALOVIRUS (HCMV) 181 9.6.1 GANCICLOVIR 182 9.6.2 VALGANCICLOVIR 182 9.6.3 CIDOFOVIR 182 9.6.4 FOSCARNET 182 9.6.5 FOMIVIRSEN 182 9.7 VARICELLA-ZOSTER VIRUS (VZV) 183 9.7.1 VALACICLOVIR 184 9.7.2 FAMCICLOVIR 184 9.7.3 ACICLOVIR 184 9.7.4 VIDARABINE 184 9.7.5 BRIVUDINE 184 9.8 HEPATITIS B VIRUS 184 9.8.1 ENTECAVIR 185 9.8.2 TENOFOVIR 185 9.8.3 TELBIVUDINE 185 9.8.4 TENOFOVIR ALAFENAMIDE 186 9.8.5 OTHERS 186 9.9 RESPIRATORY SYNCYTIAL VIRUS 186 9.9.1 RNA POLYMERASE 187 9.9.1.1 RIBAVIRIN 187 9.9.1.2 OTHERS 187 9.9.2 FUSION GLYCOPROTEIN 187 9.9.2.1 PALIVIZUMAB 188 9.9.2.2 OTHERS 188 9.10 CORONAVIRUS INFECTION 188 9.11 OTHERS 189 10 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE 190 10.1 OVERVIEW 191 10.2 GERIATRIC 194 10.2.1 MALE 194 10.2.2 FEMALE 194 10.3 CHILD 195 10.3.1 MALE 195 10.3.2 FEMALE 196 10.4 ADULT 196 10.4.1 MALE 197 10.4.2 FEMALE 197 11 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY PRODUCTS 198 11.1 OVERVIEW 199 11.2 ORAL 202 11.2.1 SOLID 203 11.2.1.1 TABLETS 203 11.2.1.2 CAPSULES 203 11.2.1.3 OTHERS 203 11.2.2 SEMISOLID 203 11.2.2.1 GELS 204 11.2.2.2 EMULSIONS 204 11.2.2.3 ELIXIRS 204 11.2.2.4 OTHERS 204 11.2.3 LIQUID 204 11.2.3.1 SOLUTIONS 204 11.2.3.2 SYRUPS 204 11.2.3.3 OTHERS 204 11.3 TOPICAL 205 11.3.1 SEMI-SOLID 206 11.3.1.1 CREAM 206 11.3.1.2 OINTMENT 206 11.3.1.3 GELS 206 11.3.1.4 OTHERS 206 11.3.2 LIQUID 206 11.3.2.1 SOLUTIONS 207 11.3.2.2 SUSPENSIONS 207 11.3.3 SOLID 207 11.3.3.1 POWDERS 207 11.3.3.2 SUPPOSITORIES 207 11.3.3.3 ENEMA 207 11.3.3.4 OTHERS 207 11.4 PARENTERAL 208 11.4.1 CONVENTIONAL DRUG DELIVERY FORMUALTIONS 209 11.4.1.1 SOLUTIONS 209 11.4.1.2 RECONSTITUTED/LYOPHILIZED 209 11.4.1.3 SUSPENSIONS 209 11.4.1.4 EMULSIONS 209 11.4.1.5 OTHERS 209 11.4.2 NOVEL DRUG DELIVERY FORMULATIONS 210 11.4.3 COLLOIDAL DISPERSIONS 210 11.4.4 LONG ACTING INJECTION FORMULATION 210 12 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE 211 12.1 OVERVIEW 212 12.2 GENERIC 215 12.3 BRANDED 215 13 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY END USER 216 13.1 OVERVIEW 217 13.2 HOSPITAL 220 13.3 SPECIALTY CENTERS 220 13.4 AMBULATORY CENTRES 221 13.5 CLINICS 221 13.6 HOME HEALTHCARE 221 13.7 OTHERS 222 14 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL 223 14.1 OVERVIEW 224 14.2 HOSPITAL PHARMACY 227 14.3 RETAIL PHARMACY 227 14.4 ONLINE PHARMACY 228 15 NORTH AMERICA ANTIVIRAL DRUGS MARKET, BY REGION 229 15.1 NORTH AMERICA 230 15.1.1 U.S 253 15.1.2 CANADA 272 15.1.3 MEXICO 289 16 NORTH AMERICA ANTIVIRAL DRUGS MARKET: COMPANY LANDSCAPE 307 16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 307 17 SWOT ANALYSIS 308 18 COMPANY PROFILE 309 18.1 GILEAD SCIENCES, INC. (2022) 309 18.1.1 COMPANY SNAPSHOT 309 18.1.2 REVENUE ANALYSIS 309 18.1.3 COMPANY SHARE ANALYSIS 310 18.1.4 PRODUCT PORTFOLIO 310 18.1.5 RECENT DEVELOPMENT 310 18.2 PFIZER INC. (2022) 311 18.2.1 COMPANY SNAPSHOT 311 18.2.2 REVENUE ANALYSIS 311 18.2.3 COMPANY SHARE ANALYSIS 312 18.2.4 PRODUCT PORTFOLIO 312 18.2.5 RECENT DEVELOPMENTS 312 18.3 SIGA TECHNOLOGIES (2022) 313 18.3.1 COMPANY SNAPSHOT 313 18.3.2 REVENUE ANALYSIS 313 18.3.3 COMPANY SHARE ANALYSIS 314 18.3.4 PRODUCT PORTFOLIO 314 18.3.5 RECENT DEVELOPMENT 314 18.4 GLAXOSMITHKLINE PLC 315 18.4.1 COMPANY SNAPSHOT 315 18.4.2 REVENUE ANALYSIS 315 18.4.3 COMPANY SHARE ANALYSIS 316 18.4.4 PRODUCT PORTFOLIO 316 18.4.5 RECENT DEVELOPMENT 316 18.5 F. HOFFMANN-LA ROCHE LTD. (2022) 317 18.5.1 COMPANY SNAPSHOT 317 18.5.2 REVENUE ANALYSIS 317 18.5.3 COMPANY SHARE ANALYSIS 318 18.5.4 PRODUCT PORTFOLIO 318 18.5.5 RECENT DEVELOPMENT 318 18.6 ABBVIE INC 319 18.6.1 COMPANY SNAPSHOT 319 18.6.2 REVENUE ANALYSIS 319 18.6.3 PRODUCT PORTFOLIO 320 18.6.4 RECENT DEVELOPMENT 320 18.7 AUROBINDO PHARMA (2022) 321 18.7.1 COMPANY SNAPSHOT 321 18.7.2 REVENUE ANALYSIS 321 18.7.3 PRODUCT PORTFOLIO 322 18.7.4 RECENT DEVELOPMENT 322 18.8 AVET PHARMACEUTICALS INC 323 18.8.1 COMPANY SNAPSHOT 323 18.8.2 PRODUCT PORTFOLIO 323 18.8.3 RECENT DEVELOPMENT 323 18.9 BRISTOLL MYERS SQUIBB (2022) 324 18.9.1 COMPANY SNAPSHOT 324 18.9.2 REVENUE ANALYSIS 324 18.9.3 PRODUCT PORTFOLIO 325 18.9.4 RECENT DEVELOPMENT 325 18.10 BIOCRYST PHARMACEUTICALS, INC. (2022) 326 18.10.1 COMPANY SNAPSHOT 326 18.10.2 REVENUE ANALYSIS 326 18.10.3 PRODUCT PORTFOLIO 327 18.10.4 RECENT DEVELOPMENT 327 18.11 CIPLA INC. (2022) 328 18.11.1 COMPANY SNAPSHOT 328 18.11.2 REVENUE ANALYSIS 328 18.11.3 PRODUCT PORTFOLIO 329 18.11.4 RECENT DEVELOPMENT 329 18.12 DR. REDDY’S LABORATORIES LTD. (2022) 330 18.12.1 COMPANY SNAPSHOT 330 18.12.2 REVENUE ANALYSIS 330 18.12.3 PRODUCT PORTFOLIO 331 18.12.4 RECENT DEVELOPMENTS 331 18.13 EMERGENT (2022) 332 18.13.1 COMPANY SNAPSHOT 332 18.13.2 REVENUE ANALYSIS 332 18.13.3 PRODUCT PORTFOLIO 333 18.13.4 RECENT DEVELOPMENT 333 18.14 HETERO 334 18.14.1 COMPANY SNAPSHOT 334 18.14.2 PRODUCT PORTFOLIO 334 18.14.3 RECENT DEVELOPMENT 334 18.15 JOHNSON & JOHNSON PRIVATE LIMITED (2022) 335 18.15.1 COMPANY SNAPSHOT 335 18.15.2 REVENUE ANALYSIS 335 18.15.3 PRODUCT PORTFOLIO 336 18.15.4 RECENT DEVELOPMENT 336 18.16 MACLEODS PHARMACEUTICALS LTD 337 18.16.1 COMPANY SNAPSHOT 337 18.16.2 PRODUCT PORTFOLIO 337 18.16.3 RECENT DEVELOPMENT 337 18.17 MERCK & CO., INC, (2022) 338 18.17.1 COMPANY SNAPSHOT 338 18.17.2 REVENUE ANALYSIS 338 18.17.3 PRODUCT PORTFOLIO 339 18.17.4 RECENT DEVELOPMENT 339 18.18 MYLAN N.V (SUBSIDIARY OF VIATRIS) (2022) 340 18.18.1 COMPANY SNAPSHOT 340 18.18.2 REVENUE ANALYSIS 340 18.18.3 PRODUCT PORTFOLIO 341 18.18.4 RECENT DEVELOPMENT 341 18.19 NAVINTA LLC 342 18.19.1 COMPANY SNAPSHOT 342 18.19.2 PRODUCT PORTFOLIO 342 18.19.3 RECENT DEVELOPMENT 342 18.20 SUN PHARMACEUTICAL INDUSTRIES LTD. (2022) 343 18.20.1 COMPANY SNAPSHOT 343 18.20.2 REVENUE ANALYSIS 343 18.20.3 PRODUCT PORTFOLIO 344 18.20.4 RECENT DEVELOPMENT 344 18.21 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2022) 345 18.21.1 COMPANY SNAPSHOT 345 18.21.2 REVENUE ANALYSIS 345 18.21.3 PRODUCT PORTFOLIO 346 18.21.4 RECENT DEVELOPMENT 346 18.22 ZYDUS PHARMACEUTICALS, INC. (2022) 347 18.22.1 COMPANY SNAPSHOT 347 18.22.2 REVENUE ANALYSIS 347 18.22.3 PRODUCT PORTFOLIO 348 18.22.4 RECENT DEVELOPMENTS 348 19 QUESTIONNAIRE 349 20 RELATED REPORTS 352